Sign In
30 Jun 2015 12:48
Ā
Ā
Ā
Ā
Tiziana Life Sciences plc
("Tiziana" or "the Company")
Ā
Ā
Result of Annual General Meeting
Ā
London, 30 June 2015 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today held its Annual General Meeting, at which all resolutions were duly passed.
Ā
Voting on the resolutions was as follows:-
Ā
Ā
Resolution | For Ā | Against | Withheld | |
1 | Annual Report & Accounts | 63,305,178 | - | 501 |
2 | Re-appointment of auditor | 63,305,679 | - | - |
3 | Re-appointment of director | 63,305,679 | - | - |
4 | Re-appointment of director | 63,305,679 | - | - |
5 | Authority to allot Shares | 63,305,617 | 33 | 29 |
6 | Dis-application of pre-emption rights | 63,305,309 | 369 | 1 |
Ā
Ā
Ā
Contacts:
Ā
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder Ā | +44 (0)20 7493 2853 |
Cairn Financial Advisers LLP (Nominated advisor) Liam Murray / Avi Robinson Ā | +44 (0)20 7148 7900 |
Beaufort Securities Limited (Broker) Saif Janjua Ā | +44 (0)20 7382 8300 |
FTI Consulting Simon Conway / Rob Winder / Natalie Garland-Collins | +44 (0)20 3727 1000 |
Ā
Ā
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.
Ā
In January 2015, the Company entered into an exclusive licence from Nerviano Medical Sciences relating to milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy.
Ā
The Company also in-licensed another clinical asset in December 2014 from Novimmune. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II asset has potential application in a wide range of autoimmune and inflammatory diseases, such as multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
Ā
Tiziana Life Sciences' research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease.
Follow the stocks
